Information  X 
Enter a valid email address

Open Orphan PLC Ord 0.1P (ORPH)

Related News

09-Apr-2021 10:00 AM

Open Orphan's hVIVO launches Disease in Motion platform

Pharmaceutical services clinical research organisation Open Orphan has announced that its subsidiary hVIVO has officially launched its Disease in Motion platform. This data-focused platform includes clinical, immunological, virological and digital (wear
06-Jan-2021 09:43 AM

Open Orphan's Venn Life Sciences renews contract with global pharmaceutical client

Specialist pharmaceutical services clinical research organisation Open Orphan has renewed its Venn Life Sciences team's contract with a major top three global pharmaceutical client to the end of December 2021. The Venn team in the Breda office in t
30-Sep-2020 09:00 AM

Open Orphan losses deepen; targets operating profitability by fourth quarter

Pharmaceutical services group Open Orphan posted a deeper first-half loss owing to costs following its acquisition of hVIVO in January. Pre-tax losses for the six months through June amounted to £6.8 million, compared to losses of £1.1 millio
24-Jun-2020 02:15 PM

Open Orphan books annual loss as expenses weigh

Pharmaceutical services company Open Orphan booked a full-year loss and said it was looking to sell non-core assets. Pre-tax losses for the year through December amounted to €6.6m, compared to losses of €1.7m for the period running between 18 J
26-May-2020 08:50 AM

Broker Forecast - finnCap issues a broker note on

finnCap today initiates coverage of (LON:ORPH) with a corporate investment rating and price target of 19p. Story provided by Broker Forecasts data provided by
27-Feb-2020 07:07 AM

Open Orphan names new CFO

Specialist CRO pharmaceutical services company has appointed a chief financial officer to the board. Leo Toole joins the firm having held senior positions at Procter and Gamble, ResMed and Sublimity Therapeutics. Through positions in multinational com
23-Jan-2020 07:30 AM

Open Orphan provides placing update

Pharmaceutical services company, Open Orphan, has confirmed that it is currently undertaking meetings with investors in connection with its proposed placing of £5 million. The company, which has a focus on orphan drugs, hopes to complete the placi
06-Jan-2020 08:27 AM

Open Orphan signs three-year consultancy deal with German pharma giant

Pharmaceutical consultancy Open Orphan has signed a new three-year contract with a tier-one German pharmaceutical company. The contract, with one of Europe's top research-driven pharmaceutical companies, guarantees significant annual revenue with wo

a d v e r t i s e m e n t